809 related articles for article (PubMed ID: 23521696)
1. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.
Yang W; Song Y; Lu YL; Sun JZ; Wang HW
Immunology; 2013 Aug; 139(4):513-22. PubMed ID: 23521696
[TBL] [Abstract][Full Text] [Related]
2. Nocardia Rubra Cell Wall Skeleton Up-Regulates T Cell Subsets and Inhibits PD-1/PD-L1 Pathway to Promote Local Immune Status of Patients With High-Risk Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia.
Chen W; Zhang Y; Zhao C; Shao S; Zhang Y; Li X; Bai X; Guo Q; Liu Q; Tang J; Zhang L
Front Immunol; 2020; 11():612547. PubMed ID: 33552075
[TBL] [Abstract][Full Text] [Related]
3. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
Yang W; Lu YP; Yang YZ; Kang JR; Jin YD; Wang HW
J Obstet Gynaecol Res; 2017 Oct; 43(10):1602-1612. PubMed ID: 28833798
[TBL] [Abstract][Full Text] [Related]
4. Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization.
Chang H; Hong JH; Lee JK; Cho HW; Ouh YT; Min KJ; So KA
J Gynecol Oncol; 2018 May; 29(3):e27. PubMed ID: 29400020
[TBL] [Abstract][Full Text] [Related]
5. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection.
Clerici M; Merola M; Ferrario E; Trabattoni D; Villa ML; Stefanon B; Venzon DJ; Shearer GM; De Palo G; Clerici E
J Natl Cancer Inst; 1997 Feb; 89(3):245-50. PubMed ID: 9017005
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of invariant NKT cells with increased IFN-γ production in persistent high-risk HPV-infected high-grade cervical intraepithelial neoplasia.
Hu T; Yang P; Zhu H; Chen X; Xie X; Yang M; Liu S; Wang H
Diagn Pathol; 2015 Apr; 10():20. PubMed ID: 25885042
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
8. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
de Gruijl TD; Bontkes HJ; Walboomers JM; Coursaget P; Stukart MJ; Dupuy C; Kueter E; Verheijen RH; Helmerhorst TJ; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
J Gen Virol; 1999 Feb; 80 ( Pt 2)():399-408. PubMed ID: 10073700
[TBL] [Abstract][Full Text] [Related]
9. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions.
Bais AG; Beckmann I; Lindemans J; Ewing PC; Meijer CJ; Snijders PJ; Helmerhorst TJ
J Clin Pathol; 2005 Oct; 58(10):1096-100. PubMed ID: 16189158
[TBL] [Abstract][Full Text] [Related]
10. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix.
Sharma A; Rajappa M; Saxena A; Sharma M
Int J Gynecol Cancer; 2007; 17(4):879-85. PubMed ID: 17343606
[TBL] [Abstract][Full Text] [Related]
11. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
Chan PK; Liu SJ; Cheung JL; Cheung TH; Yeo W; Chong P; Man S
J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
[TBL] [Abstract][Full Text] [Related]
12. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study on cervical intraepithelial neoplasia with high-risk HPV infection among pregnant women].
He Y; Wu YM; Wang T; Song F; Wang Y; Zhao Q; Kong WM; Duan W; Zhu L; Zhang WY
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):598-602. PubMed ID: 23141180
[TBL] [Abstract][Full Text] [Related]
14. Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia.
Shepherd PS; Rowe AJ; Cridland JC; Coletart T; Wilson P; Luxton JC
J Gen Virol; 1996 Apr; 77 ( Pt 4)():593-602. PubMed ID: 8627247
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of programmed cell death ligand 1 in patients with CIN and its correlation with human papillomavirus infection and CIN persistence.
Sancakli Usta C; Altun E; Afsar S; Bulbul CB; Usta A; Adalı E
Infect Agent Cancer; 2020; 15():47. PubMed ID: 32695218
[TBL] [Abstract][Full Text] [Related]
16. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Dibbern ME; Bullock TN; Jenkins TM; Duska LR; Stoler MH; Mills AM
Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
[TBL] [Abstract][Full Text] [Related]
17. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
[TBL] [Abstract][Full Text] [Related]
18. IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia.
Matsumoto K; Yasugi T; Oki A; Fujii T; Nagata C; Sekiya S; Hoshiai H; Taketani Y; Kanda T; Kawana T; Yoshikawa H
Cancer Lett; 2006 Jan; 231(2):309-13. PubMed ID: 16399232
[TBL] [Abstract][Full Text] [Related]
19. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
Mesher D; Cuschieri K; Hibbitts S; Jamison J; Sargent A; Pollock KG; Powell N; Wilson R; McCall F; Fiander A; Soldan K
J Clin Pathol; 2015 Feb; 68(2):135-40. PubMed ID: 25410654
[TBL] [Abstract][Full Text] [Related]
20. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
Kadish AS; Timmins P; Wang Y; Ho GY; Burk RD; Ketz J; He W; Romney SL; Johnson A; Angeletti R; Abadi M;
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):483-8. PubMed ID: 12010863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
